Antoaneta Tomova
Research Subjects
Antoaneta Tomova has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Allison Moreau
10Pfizer Inc., La Jolla, California
16 shared publications - Antonio Giordano
Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
16 shared publications - Erika Hamilton
Sarah Cannon Research Institute, Nashville, TN, USA
16 shared publications - Feng Liu
Pfizer Inc., San Diego, CA, USA
16 shared publications - Heather Neumann
10Pfizer Inc., La Jolla, California
16 shared publications - Igor Bondarenko
Dnipropetrovsk State Medical Academy, Dnipropetrovsk, Ukraine
16 shared publications
Latest Publications
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Supplementary Figure S1. Change from baseline in tumor biomarkers following monotherapy or combination treatment - biomarker analysis set.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Supplementary Figure S1. Change from baseline in tumor biomarkers following monotherapy or combination treatment - biomarker analysis set.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Table 3 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Summary of DLT by system organ class and preferred term (all causalities). DLT—evaluable analysis set.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 3 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Summary of DLT by system organ class and preferred term (all causalities). DLT—evaluable analysis set.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Table 4 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Summary of best overall response and objective response (confirmed) based on investigator assessment (RECIST version 1.1)—response-evaluable set, part 2.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 4 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Summary of best overall response and objective response (confirmed) based on investigator assessment (RECIST version 1.1)—response-evaluable set, part 2.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Data from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Purpose:The discovery that cyclin E overexpression is a key cyclin-dependent kinase (CDK) 4/6 inhibitor resistance mechanism has reinvigorated interest in targeting CDK2 and the simultaneous inhibition of CDK2/4/6 as a novel therapeutic approach. This first-in-human study assessed the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of PF-06873600, the first-in-class inhibitor of CDK2/4/6.Patients and Methods:Dose escalation included 78 patients with advanced breast cancer, triple-negative breast cancer, or ovarian cancer who received oral PF-06873600 at doses ranging from 1 to 50 mg twice daily (part 1A, n = 51) or PF-06873600 with endocrine therapy (part 1B, n = 16; part 1C, n = 11) to determine the recommended dose for expansion (RDE). Dose expansion (part 2A, n = 45; part 2C, n = 28) assessed preliminary antitumor activity, safety, and tolerability at the RDE in combination with fulvestrant in patients with hormone receptor+/HER2− metastatic breast cancer. Pharmacodynamics and translational readouts were assessed by measuring phosphorylated Rb and Ki67 in tumor biopsies and ctDNA.Results:The RDE of PF-06873600 was 25 mg twice daily. During dose escalation, 6 of 42 (14.3%) evaluable patients had treatment-related dose-limiting toxicities. The most common all-causality adverse events (N = 151) were nausea (62.9%), anemia (44.4%), and fatigue (43.7%). Reductions in Ki67-positive cells, phosphorylated Rb histo-score, and ctDNA levels were observed. Three RECIST partial responses (PR) were observed in part 1. In part 2A, there were three PRs (objective response rate, 6.7%; 95% confidence interval, 1.4%–18.3%), and in part 2C, there were five PRs (objective response rate, 22.7%; 95% confidence interval, 7.8%–45.4%).Conclusions:PF-06873600 demonstrated a benefit–risk profile consistent with the CDK4/6 inhibitor class of drugs, with preliminary clinical activity in hormone receptor+/HER2− metastatic breast cancer.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Purpose:The discovery that cyclin E overexpression is a key cyclin-dependent kinase (CDK) 4/6 inhibitor resistance mechanism has reinvigorated interest in targeting CDK2 and the simultaneous inhibition of CDK2/4/6 as a novel therapeutic approach. This first-in-human study assessed the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of PF-06873600, the first-in-class inhibitor of CDK2/4/6.Patients and Methods:Dose escalation included 78 patients with advanced breast cancer, triple-negative breast cancer, or ovarian cancer who received oral PF-06873600 at doses ranging from 1 to 50 mg twice daily (part 1A, n = 51) or PF-06873600 with endocrine therapy (part 1B, n = 16; part 1C, n = 11) to determine the recommended dose for expansion (RDE). Dose expansion (part 2A, n = 45; part 2C, n = 28) assessed preliminary antitumor activity, safety, and tolerability at the RDE in combination with fulvestrant in patients with hormone receptor+/HER2− metastatic breast cancer. Pharmacodynamics and translational readouts were assessed by measuring phosphorylated Rb and Ki67 in tumor biopsies and ctDNA.Results:The RDE of PF-06873600 was 25 mg twice daily. During dose escalation, 6 of 42 (14.3%) evaluable patients had treatment-related dose-limiting toxicities. The most common all-causality adverse events (N = 151) were nausea (62.9%), anemia (44.4%), and fatigue (43.7%). Reductions in Ki67-positive cells, phosphorylated Rb histo-score, and ctDNA levels were observed. Three RECIST partial responses (PR) were observed in part 1. In part 2A, there were three PRs (objective response rate, 6.7%; 95% confidence interval, 1.4%–18.3%), and in part 2C, there were five PRs (objective response rate, 22.7%; 95% confidence interval, 7.8%–45.4%).Conclusions:PF-06873600 demonstrated a benefit–risk profile consistent with the CDK4/6 inhibitor class of drugs, with preliminary clinical activity in hormone receptor+/HER2− metastatic breast cancer.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Supplementary Table S2. Summary of treatment-emergent adverse events (>15%) by preferred term and maximum CTCAE grade (treatment-related, all cycles)—safety analysis set, Part 2.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Supplementary Table S2. Summary of treatment-emergent adverse events (>15%) by preferred term and maximum CTCAE grade (treatment-related, all cycles)—safety analysis set, Part 2.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Supplementary Figure S2. ctDNA molecular response.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Supplementary Figure S2. ctDNA molecular response.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Median plasma PF-06873600 concentration–time profile. A, Following single oral doses on cycle 1 day 1. B, Following multiple oral doses on cycle 1 day 15. *Part 1 PF-06873600 25 mg twice daily (BID) IR combined with part 1A PF-06873600 25 mg BID IR, part 1A PF-06873600 25 mg BID biomarker, and part 1C PF-06873600 MR 20 mg lead-in IR 25 mg BID. IR, immediate release; MR, modified release.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Median plasma PF-06873600 concentration–time profile. A, Following single oral doses on cycle 1 day 1. B, Following multiple oral doses on cycle 1 day 15. *Part 1 PF-06873600 25 mg twice daily (BID) IR combined with part 1A PF-06873600 25 mg BID IR, part 1A PF-06873600 25 mg BID biomarker, and part 1C PF-06873600 MR 20 mg lead-in IR 25 mg BID. IR, immediate release; MR, modified release.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Table 2 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Summary of TEAEs (>15%) by preferred term and maximum CTCAE grade in descending frequency order (treatment-related, all cycles)—safety analysis set parts 1 and 2 (N = 151).
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Summary of TEAEs (>15%) by preferred term and maximum CTCAE grade in descending frequency order (treatment-related, all cycles)—safety analysis set parts 1 and 2 (N = 151).
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Supplementary Table S4. Descriptive summary of plasma PF-06873600 PK parameters following the immediate release, modified release short duration, and modified release long duration formulations (Part 1C)—PK parameter analysis set.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Supplementary Table S4. Descriptive summary of plasma PF-06873600 PK parameters following the immediate release, modified release short duration, and modified release long duration formulations (Part 1C)—PK parameter analysis set.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Overall study schema. a25 mg twice daily (BID) was the RDE. bOne patient was untreated. AI, aromatase inhibitor; CDK, cyclin-dependent kinases; CDK4/6i, CDK4/6 inhibitor; ET, endocrine therapy; Ful, fulvestrant; HER2−, human epidermal growth receptor 2-negative; HR+, hormone receptor-positive; IR, immediate release; Let, letrozole; mBC, metastatic breast cancer; MR, modified release; RDE, recommended dose for expansion; TNBC, triple negative breast cancer.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Overall study schema. a25 mg twice daily (BID) was the RDE. bOne patient was untreated. AI, aromatase inhibitor; CDK, cyclin-dependent kinases; CDK4/6i, CDK4/6 inhibitor; ET, endocrine therapy; Ful, fulvestrant; HER2−, human epidermal growth receptor 2-negative; HR+, hormone receptor-positive; IR, immediate release; Let, letrozole; mBC, metastatic breast cancer; MR, modified release; RDE, recommended dose for expansion; TNBC, triple negative breast cancer.